Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Development of radiolabelled histone deacetylase inhibitors for PET imaging study

  • Hee-Kwon Kim (Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Jeonbuk National University Medical School and Hospital)
  • Received : 2020.12.15
  • Accepted : 2020.12.29
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Histone Deacetylases (HDACs) are enzymes that have control gene expression regulation and cell state. In additions, inhibitions of HDACs are associated with growth arrest, differentiation, or apoptosis of tumor cell. Thus HDAC inhibition is one of the interesting biological targets. A variety of HDAC inhibitors has been developed by many scientists, and some of chemical structures related with HDAC inhibitors were modified to give radiolabeled HDAC inhibitors for positron emission tomography (PET) study. In this highlight review, the development of radiolabeled HDAC inhibitors for PET study are described.

Keywords

Acknowledgement

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1B07047572).

References

  1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-45.
  2. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
  3. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009:23:781-783.
  4. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nature Rev Genet 2007;8:286-298.
  5. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-294.
  6. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606.
  7. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-352.
  8. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749.
  9. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93:5705-5708.
  10. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101:18030-18035.
  11. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007;74:659-671.
  12. Mukhopadhyay U, Tong W, Gelovani J, Alauddin M. Radiosynthesis of 6-([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA) for PET imaging of histone deacetylase (HDAC). J Label Comp Radiopharm 2006;49:997-1006.
  13. Nishii R, Mukhopadhyay U, Yeh H, Sohomonyan S, Volgin A, Alauddin M, et al. Non-invasive imaging of histone deacetylase activity in human breast carcinoma xenografts in rats using positron emission tomography (PET) with [18F]FAHA. J Nucl Med 2007;48S2:34.
  14. Nishii R, Mukhopadhyay U, Yeh H, Sohomonyan S, Volgin A, Alauddin M, et al. PET imaging of histone deacetylase activity in rat brain using 6-([18F] fluoroacetamide)-1-hexanoicanilide ([18F]FAHA). J Nucl Med 2007;48S2:336.
  15. Reid AE, Hooker J, Shumay E, Logan J, Shea C, Kim SW, Collins S, Xu Y, Volkov N, Fowler JS. Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nucl Med Biol 2009;36:247-258.
  16. Zeglis BM, Pillarsetty NVK, Divilov V, Blasberg RA, Lewis JS, The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol 2011;36:683-696.
  17. Hendricks JA, Keliher EJ, Marinelli B, Reiner T, Weissleder R, Mazitschek R. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem 2011;54:5576-5582.
  18. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013;31:2128- 2135.
  19. Kiany S, Huang G, Kleinerman ES. Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology 2017;6:e1333214-e1333214.
  20. Jespersen H, Bagge RO, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer 2019;19:415.
  21. Azad NS, Shirai K, McRee AJ, Opyrchal M, Johnson DB, Ordentlich P, Brouwer S, Sankoh S, Schmidt EV, Meyers ML, Johnson ML, ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. J Clin Oncol 2018;36:3557-3557.
  22. Mokhtari RB, Baluch N, Tsui MKH, Kumar S, Homayouni TS, Aitken K, Das B, Baruchel S, Yeger H. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC cancer 2017;17:156-156.
  23. Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N, Fowler JS. Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: pharmacokinetic studies of [11C]MS-275 using positron emission tomography. ACS Chem Neurosci 2010;1:65-73.
  24. Seo YJ, Kang Y, Muench L, Reid A, Caesar S, Jean L, Wagner F, Holson E, Haggarty SJ, Weiss P, King P, Carter P, Volkow ND, Fowler JS, Hooker JM, Kim SW. Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. ACS Chem Neurosci 2014;5:588-596.